Bivalirudin Phase 2 ECMO Trial Update: Still Recruiting as of May 2026

A Phase 2 clinical trial evaluating bivalirudin was updated on May 8, 2026. The trial, titled "BivaLirudin versUS Heparin in Extracorporeal Membrane Oxygenation," is registered under identifier NCT05959252. According to the latest status update, the trial is currently in the recruiting phase. The study is designed to compare bivalirudin against heparin in the context of extracorporeal membrane oxygenation, based on the trial title. No results have been posted as part of this update, and the current record reflects only recruitment status, not efficacy or safety outcomes. Bivalirudin is an approved compound, and this trial represents ongoing clinical investigation within an approved use context. Readers should note that a Phase 2 status and recruiting designation indicate the trial is actively enrolling participants but has not reached a point of reporting comparative outcomes. No additional trial details, such as enrollment numbers or specific endpoints, were included in this update. For more background on bivalirudin, including its approved regulatory status and general profile, readers can consult the compound overview.